Lorraine D. Hernandez

TL;DR: Platensimycin demonstrates strong, broad-spectrum Gram-positive antibacterial activity by selectively inhibiting cellular lipid biosynthesis through the selective targeting of β-ketoacyl-(acyl-carrier-protein (ACP) in the synthetic pathway of fatty acids.

TL;DR: Platencin shows potent in vivo efficacy without any observed toxicity, emphasizing the fact that more antibiotics with novel structures and new modes of action can be discovered by using this antisense differential sensitivity whole-cell screening paradigm.

TL;DR: The data provided a molecular basis for neutralization by this clinically important antibody and are consistent with a model wherein a single molecule of bezlotoxumab neutralizes TcdB by binding via its two Fab regions to two epitopes within the N-terminal half of the TCDB CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells.

TL;DR: It is shown that the antitoxin antibodies are protective in multiple murine models of CDI, including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice, providing a mechanistic basis for the prevention of recurrent disease observed in CDI patients in clinical trials.

TL;DR: Combined with in vitro neutralization data, epitope modeling will enhance the ability to predict the coverage of new and emerging strains by actoxumab-bezlotoxumAB in the clinic.